日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study

在新生血管性年龄相关性黄斑变性(AMD)中,从阿柏西普过渡到雷珠单抗生物类似药(TRANSFORM试验):一项多中心观察性研究

Chakraborty, Debdulal; Boral, Subhendu; Sinha, Tushar Kanti; Das, Arnab; Mukherjee, Angshuman; Majumdar, Saptorshi; Bhattacharya, Ranabir; Maitra, Ritobroto

Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study

在印度真实世界情境下,Brolucizumab 与 aflibercept 治疗难治性糖尿病性黄斑水肿的比较——BRADIR 研究

Chakraborty, Debdulal; Sharma, Ashish; Mondal, Soumen; Sheth, Jay; Sinha, Tushar Kanti; Boral, Subhendu; Mukherjee, Angshuman; Bhattacharya, Ranabir; Maitra, Ritobroto

Patterns of understory invasion in invasive timber stands of a tropical sky island

热带天空岛入侵性林木林下层植被入侵模式

Jobin, Varughese; Das, Arundhati; Harikrishnan, C P; Chanda, Ritobroto; Lawrence, Swapna; Robin, V V

Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence

雷尼珠单抗生物类似药与创新药在新生血管性年龄相关性黄斑变性中的比较(BALANCE试验):真实世界证据

Chakraborty, Debdulal; Mondal, Soumen; Boral, Subhendu; Das, Arnab; Sinha, Tushar Kanti; Majumdar, Saptorshi; Bhattacharya, Ranabir; Maitra, Ritobroto

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study

比较创新药与生物类似药雷珠单抗治疗糖尿病性黄斑水肿的疗效:一项多中心回顾性研究

Chakraborty, Debdulal; Sengupta, Sabyasachi; Mondal, Soumen; Boral, Subhendu; Das, Arnab; Sinha, Tushar Kanti; Bhattacharya, Ranabir; Maitra, Ritobroto

Stereochemical investigation of conjugate additions of carbon- and heteronucleophiles to ring-substituted nitrosocyclohexenes

碳亲核试剂和杂亲核试剂与环取代的亚硝基环己烯共轭加成反应的立体化学研究

Sengupta, Ritobroto; Witek, Jason A; Weinreb, Steven M